Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993 ↗
Vertex Pharmaceuticals announces financial results for the second quarter after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Monday? ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Stock Plummets 13% After Discontinuing VX-993 Despite Q2 Earnings Beat ↗
Vertex Q2 2025 earnings beat estimates, but stock dropped 13% after discontinuing acute pain drug VX-993. Focus remains on CF and other key programs. 
Via Chartmill
Topics Earnings
News headline image
Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat ↗
Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing. 
Via Investor's Business Daily
Topics ETFs
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full... 
Via StockStory
Topics Earnings
News headline image
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus ↗
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
News headline image
What To Expect From Vertex Pharmaceuticals’s (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
3 Unstoppable Stocks to Buy in August ↗
Here are hot stocks to buy in a hot month. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Examining the Future: Vertex Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗
These growth stocks have plenty of room to run. 
Via The Motley Fool
News headline image
The 3 Things That Matter for Vertex Pharmaceuticals Now ↗
Some of these developments could improve the company's prospects. 
Via The Motley Fool
News headline image
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making to Buy Right Now ↗
Via The Motley Fool
News headline image
3 Top Growth Stocks to Buy in the Second Half of 2025 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
3 Cash-Burning Stocks Walking a Fine Line
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy Economy
News headline image
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again) ↗
Via The Motley Fool
Topics Artificial Intelligence Energy World Trade
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
With just a little bit of a deeper look, these businesses are positioned for long-term growth. 
Via The Motley Fool
News headline image
Motley Fool Co-Founder David Gardner Reviews Stock Picks ↗
Via The Motley Fool
News headline image
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz ↗
Via The Motley Fool
Topics Stocks
News headline image
3 No-Brainer Stocks to Buy in July ↗
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 In Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU ↗
Vertex announced on Tuesday that eligible patients in Ireland, Denmark, and Germany will have access to Alyftrek shortly after receiving regulatory approval from the relevant authorities. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.